Dr. Anton Orlin, MD

Dr. Orlin practices at Retinovitreous Associates Ltd in Plymouth Meeting, Pennsylvania.

Dr. Orlin's NPI, 1720138498, was assigned on January 12, 2007. Dr. Orlin graduated from Perelman School of Med at the University of Pennsylvania in 2006. Dr. Orlin holds Pennsylvania license MD472031.

Dr. Orlin's primary practice is Retinovitreous Associates Ltd, at 4060 Butler Pike, Plymouth Meeting, PA 19462 in Montgomery County. The practice phone is (800) 331-6634.

Dr. Orlin's primary practice is Retinovitreous Associates Ltd in Plymouth Meeting, Pennsylvania. Dr. Orlin is also affiliated with Wills Eye Hospital. Dmand AI also links Dr. Orlin to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Orlin practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Orlin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Orlin's licenses on file in 3 states: Pennsylvania, Delaware and New Jersey.

CMS data shows 19,458 Medicare services from Dr. Orlin across 21 procedure codes in 2024, for 1,245 Medicare patients. Medicare paid $2,689,415 for them.

CMS counts 1,245 Medicare patients who saw Dr. Orlin in 2024. The largest group is 65 to 74, with 538 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Orlin's median patient age at 70, with 55% women.

In 2024, Dr. Orlin wrote 433 Medicare Part D claims for 154 patients. 52% of them were for generic drugs. CMS names the drug for 342 of them, across 8 drugs with 11 or more claims each, at $17,131 in total drug cost. In 2023, CMS named 56 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Orlin for performance year 2024, reported as part of a group. Dr. Orlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 54 papers to Dr. Orlin, published from 2011 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Visual Acuity, Tomography, Optical Coherence and Fluorescein Angiography. Dr. Orlin has published most often in Retina. Dr. Orlin's most frequent co-authors are Donald J. D'Amico, MD, Szilard Kiss, MD and Kyle Davis Kovacs, MD.

Dmand AI links Dr. Orlin to 1 clinical trial. Conditions studied include Retinopathy of Prematurity and Infant, Premature, Diseases. Open Payments lists research payments to Dr. Orlin that name 1 trial.

CMS Open Payments shows 47 general payments to Dr. Orlin from 10 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 84% of the total. Genentech, Inc. paid the most, $11,757. It also lists 8 research payments totaling $722 in 2019, naming 1 clinical trial.

Dr. Orlin graduated from Perelman School of Med at the University of Pennsylvania in 2006.